Where this LCD applies
Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.
| Contract | Contractor | Type | States |
|---|---|---|---|
| 06101 | Wellpoint Federal | MAC - Part A | IL |
| 06201 | Wellpoint Federal | MAC - Part A | MN |
| 06301 | Wellpoint Federal | MAC - Part A | WI |
| 06102 | Wellpoint Federal | MAC - Part B | IL |
| 06202 | Wellpoint Federal | MAC - Part B | MN |
| 06302 | Wellpoint Federal | MAC - Part B | WI |
| 13101 | Wellpoint Federal | A and B and HHH MAC | CT |
| 13201 | Wellpoint Federal | A and B and HHH MAC | NY |
| 13102 | Wellpoint Federal | A and B and HHH MAC | CT |
| 13202 | Wellpoint Federal | A and B and HHH MAC | NY |
| 13282 | Wellpoint Federal | A and B and HHH MAC | NY |
| 13292 | Wellpoint Federal | A and B and HHH MAC | NY |
| 14411 | Wellpoint Federal | A and B and HHH MAC | RI |
| 14211 | Wellpoint Federal | A and B and HHH MAC | MA |
| 14311 | Wellpoint Federal | A and B and HHH MAC | NH |
| 14511 | Wellpoint Federal | A and B and HHH MAC | VT |
| 14111 | Wellpoint Federal | A and B and HHH MAC | ME |
| 14112 | Wellpoint Federal | A and B and HHH MAC | ME |
| 14212 | Wellpoint Federal | A and B and HHH MAC | MA |
| 14312 | Wellpoint Federal | A and B and HHH MAC | NH |
| 14512 | Wellpoint Federal | A and B and HHH MAC | VT |
| 14412 | Wellpoint Federal | A and B and HHH MAC | RI |
Billing and coding article A56793: diagnoses and procedure codes
Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A56793 (Billing and Coding: Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.
Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.
A56793: Billing and Coding: Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases (Billing and Coding, effective 2026-04-01)
- Covered ICD-10-CM codes
- 89
- 3 groups
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 4
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| C88.80 | Other malignant immunoproliferative diseases not having achieved remission |
| C92.00 | Acute myeloblastic leukemia, not having achieved remission |
| C92.02 | Acute myeloblastic leukemia, in relapse |
| C92.10 | Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission |
| C92.12 | Chronic myeloid leukemia, BCR/ABL-positive, in relapse |
| C92.20 | Atypical chronic myeloid leukemia, BCR/ABL-negative, not having achieved remission |
| C92.22 | Atypical chronic myeloid leukemia, BCR/ABL-negative, in relapse |
| C92.30 | Myeloid sarcoma, not having achieved remission |
| C92.32 | Myeloid sarcoma, in relapse |
| C92.40 | Acute promyelocytic leukemia, not having achieved remission |
| C92.42 | Acute promyelocytic leukemia, in relapse |
| C92.50 | Acute myelomonocytic leukemia, not having achieved remission |
| C92.52 | Acute myelomonocytic leukemia, in relapse |
| C92.60 | Acute myeloid leukemia with 11q23-abnormality not having achieved remission |
| C92.62 | Acute myeloid leukemia with 11q23-abnormality in relapse |
| C92.90 | Myeloid leukemia, unspecified, not having achieved remission |
| C92.92 | Myeloid leukemia, unspecified in relapse |
| C92.A0 | Acute myeloid leukemia with multilineage dysplasia, not having achieved remission |
| C92.A2 | Acute myeloid leukemia with multilineage dysplasia, in relapse |
| C92.Z0 | Other myeloid leukemia not having achieved remission |
| C92.Z2 | Other myeloid leukemia, in relapse |
| C93.00 | Acute monoblastic/monocytic leukemia, not having achieved remission |
| C93.02 | Acute monoblastic/monocytic leukemia, in relapse |
| C93.10 | Chronic myelomonocytic leukemia not having achieved remission |
Procedure codes: 81450, 81451, 81455, 81456.
Coverage indications, limitations and medical necessity
Acute Myelogenous Leukemia (AML)
Indications
Genomic Sequential Analysis Panel will be considered reasonable and necessary in the evaluation of blood or bone marrow samples in the following clinical circumstances:
• Genomic Sequential Analysis Panel will be considered reasonable and necessary in the evaluation of blood or bone marrow samples for newly diagnosed or relapsed/refractory AML patients who are candidates for treatment, regardless of karyotype findings.
• Previously diagnosed patients with AML, who have not responded to induction chemotherapy, or who have progressed following induction. The patient must be a candidate for transplantation at the time of the testing.
• Patients with AML, who have responded to treatment, either chemotherapy or transplantation, with evidence of relapse.
Myelodysplastic Syndromes (MDS)
Indications
Genomic Sequential Analysis Panel will be considered reasonable and necessary in the evaluation of blood or bone marrow samples in the following clinical circumstances:
• Patients with clinical signs or symptoms of myelodysplastic syndromes (MDS) or myelodysplastic/myeloproliferative overlap syndromes (MDS/MPN), in whom clinical, laboratory, and pathologic assessment are nondiagnostic.
• Newly diagnosed MDS or MDS/MPN patients either
• stratified by the IPSS or IPSS-R as intermediate risk, or
• in MDS with ringed sideroblasts/RARS.
• Repeat Genomic Sequential Analysis Panel testing is considered reasonable and necessary in MDS after initial diagnosis and risk stratification.
Myeloproliferative Neoplasms (MPN)
Indications and Limitations of Coverage
Genomic Sequential Analysis Panel will be considered reasonable and necessary in the evaluation of blood or bone marrow samples in the following circumstances:
• Diagnosis: Clinical signs or symptoms of myeloproliferative neoplasm (MPN) or myelodysplastic/myeloproliferative overlap syndromes (MDS/MPN) when
• clinical, laboratory, and pathologic assessment are nondiagnostic; and
• CML excluded (BCR-ABL1 negative) 1,2
• Risk Stratification: Newly diagnosed PMF not already classified as high-risk by Dynamic International Prognostic Scoring System (DIPSS) Plus 1,3,4
• Monitoring: Higher-risk MF (INT-1, INT-2, High-Risk) with progression on therapy 1
Summary of evidence (opening)
Acute Myelogenous Leukemia (AML)
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts, primarily in the peripheral blood and bone marrow. The American Cancer Society estimates that approximately 60,000 new cases of leukemia will be diagnosed in 2016, with one-third classified as acute myelogenous leukemia (AML). It accounts for the most annual deaths from leukemia in the United States. The median age of diagnosis is 67, with 54% diagnosed at 65 years or older (and approximately one third diagnosed at 75 years of age or older). Moreover, AML lies at one end of a spectrum of neoplastic myeloid diseases that includes myelodysplastic syndromes (MDS), which often progress to AML, and which are even more common in patients of advanced age, with an incidence of approximately 1/5000 patients over the age of 70.
AML is an aggressive disease that requires immediate diagnosis and treatment, with an average 5 yr survival rate of 28%, depending on a number of clinical and biologic variables, including acquired genetic alterations within the leukemic cells. Early treatment of AML generally consists of high-dose cytotoxic chemotherapy to induce remission, followed by consolidation (i.e., post-remission) chemotherapy and/or bone marrow transplantation.
Steadily accumulating genomic evidence shows that certain acquired genetic alterations within the leukemic cells are strong predictors of prognosis in AML and, accordingly, are essential factors in the decision whether a patient should undergo bone marrow transplantation (1-4). These alterations have been set aside as determinants of independent diagnostic categories in WHO AML guidelines, and as essential for AML management in NCCN guidelines (5,6).
The contractor cites 31 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.
Dates, lineage and related policies
- Original determination effective
- 2018-08-01
- Current revision effective
- 2026-04-01
- Last reviewed by the contractor
- 2024-12-29
- MCD version
- 18
The contractor lists 2 National Coverage Determinations as related: NCD 190.3 Cytogenetic Studies, NCD 90.2 Next Generation Sequencing (NGS). Where an NCD speaks, it controls; the LCD can only address what the NCD leaves open.
Other related documents: A59984 (Response to Comments).
Using this policy on a claim
Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Wellpoint Federal hub lists every other active policy from the same contractor.
For teams evaluating QuickIntell software
Where QuickIntell fits with this policy
If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions
What does LCD L37606 cover?
Genomic Sequential Analysis Panel will be considered reasonable and necessary in the evaluation of blood or bone marrow samples in the following clinical circumstances: The full 307-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.
Which states does LCD L37606 apply to?
Wellpoint Federal applies it to Medicare claims in 10 states: CT, IL, MA, ME, MN, NH, NY, RI, VT, WI. It binds only that contractor; outside these jurisdictions the same service is judged under the local contractor's own policy or, where none exists, claim by claim.
Which diagnosis codes support medical necessity under LCD L37606?
The companion billing and coding article A56793 lists 89 ICD-10-CM codes in 3 groups that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.
How do I appeal a denial under LCD L37606?
A denial under LCD L37606 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A56793's 89 covered diagnosis codes, then file a redetermination with Wellpoint Federal within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Coverage Database, current LCD exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file lcd.csvSHA-256 2e0eda3351aa3d47…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
- ICD-10-CM FY2027 code descriptionsVersion FY2027 · effective 2026-10-01 · file icd10cm_codes_2027.txtSHA-256 3c0583a38ee0e848…
Disclaimer
The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.